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http://dx.doi.org/10.1016/j.ccell.2015.05.005SUMMARYThe significance of ERG in human prostate cancer is unclear because mouse prostate is resistant to ERG-
mediated transformation. We determined that ERG activates the transcriptional program regulated by
YAP1 of the Hippo signaling pathway and found that prostate-specific activation of either ERG or YAP1 in
mice induces similar transcriptional changes and results in age-related prostate tumors. ERG binds to chro-
matin regions occupied by TEAD/YAP1 and transactivates Hippo target genes. In addition, in human luminal-
type prostate cancer cells, ERG binds to the promoter of YAP1 and is necessary for YAP1 expression. These
results provide direct genetic evidence of a causal role for ERG in prostate cancer and reveal a connection
between ERG and the Hippo signaling pathway.INTRODUCTION
The development of effective prevention and treatment strategies
for prostate cancer requires understanding the critical molecular
alterations that drive the initiation of neoplasia and subsequent
development of malignant characteristics. The notable finding
that recurrent chromosomal recombination events result in ERG
oncogene overexpression in prostate cancers provides compel-
ling evidence supporting the hypothesis that ERG, and potentially
other ETS family transcription factors, function as key drivers of
prostate carcinogenesis (Tomlins et al., 2005). ETS family gene
rearrangements occur in 20%–50%of all human prostate adeno-
carcinomas, depending on racial background, and are found in
precursor lesions and across all histological grades and tumor
stages (Sreenath et al., 2011; Tomlins et al., 2005).Significance
Developing therapeutic approaches to inhibit ERG activity is c
responsible for ERG-mediated transformation. We found that
and determined that genetic activation of YAP1 inmouse prost
neoplasms that are similar to tumors caused by ERG upregula
ERG and the Hippo pathway. Moreover, we demonstrate th
inhibits the orthotopic growth of pre-established ERG-positiv
clinical strategies targeting YAP1 in tumors with ERG rearrangCause and effect studies of phenotypic changes resulting
from high ERG activity have been conducted using a spectrum
of cell lines, xenografts, and genetically engineered mouse
(GEM) models. Knockdown of ERG in VCaP prostate adeno-
carcinoma cells, a line that harbors a functional TMPRSS2-
ERG rearrangement (Tomlins et al., 2005) substantially reduces
cell invasion and attenuates proliferation (Gupta et al., 2010;
Tomlins et al., 2008; Wang et al., 2008). Consistent with loss-
of-function studies in VCaP cells, overexpression of ERG or
other ETS family genes in immortalized prostate epithelial cell
lines results in a substantial increase in cell invasion (Klezovitch
et al., 2008; Tomlins et al., 2007). At the molecular level,
ERG has been shown to influence androgen receptor signaling,
induce a repressive epigenetic program via activation of EZH2,
activate Wnt pathway signaling, and promote NFkB-mediatedhallenged by a paucity of knowledge about the mechanisms
ERG activates the transcriptional output regulated by YAP1
ate epithelium is sufficient to induce age-dependent prostate
tion. These results reveal an important connection between
at pharmacological inhibition of YAP1 activity prominently
e human prostate tumors, supporting the development of
ements.
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transcription (Chen et al., 2013; Gupta et al., 2010; Wang et al.,
2011; Yu et al., 2010).
To confirm a causal role for ERG in the genesis of prostate
cancer, several GEM models have been constructed that
express ERG specifically in prostate epithelial cells. These
models are notable for a range of relatively subtle phenotypic
changes that include the partially penetrant formation of focal
precancerous lesions or focal hyperplasia (Baena et al., 2013;
Chen et al., 2013; Klezovitch et al., 2008; Tomlins et al.,
2008), or a complete absence of any discernable phenotype
(Carver et al., 2009a, 2009b; King et al., 2009). In contrast to
the minimal oncogenic effects observed in ERG transgenic
mice, when combined with Tp53 loss or Pten inactivation,
ERG promotes invasive and metastatic phenotypes. The differ-
ences in ERG-mediated effects between human and mouse
cells and between the different GEM models can be potentially
explained by the level of transgene expression; however, the
relative levels of ERG protein expression in many transgenic
models have either not been reported (Carver et al., 2009a,
2009b; King et al., 2009) or found to be low in comparison to
levels in human prostate cancer (Baena et al., 2013; Casey
et al., 2012). To better understand the importance of ERG
and determine the mechanism(s) by which it can promote
neoplasia, we analyzed transgenic mice expressing ERG in
prostate epithelium at levels comparable to those found in
ERG-rearranged primary human prostate cancers in vivo.
YAP1 is acomponent of thecanonical Hipposignalingpathway
that comprises a cascade of kinases that includes the Hippo/
MST1-2 kinases, the adaptor Sav1, and the LATS1/2 kinases.
Hippo signaling culminates in the phosphorylation and conse-
quent inactivation of the transcriptional co-activators YAP1 and
TAZ by LATS1/2, which suppresses the TEAD-dependent
expression of a network of genes that promote cell proliferation
and survival. Studies in mouse models have shown that LATS1/
2 kinases exert tumor suppressive effects and YAP1 functions
as an oncogene (Pan, 2010). Hippo pathway activity is strongly
implicated in the pathogenesis of human medulloblastomas,
oral squamous-cell carcinomas, and carcinomas of the lung,
pancreas, esophagus, liver, and mammary gland (Pan, 2010).
While previous studies have determined that the Hippo kinases
MST1/2 and LATS1/2 are downregulated andYAP is upregulated
in a subset of primary human prostate cancers (Cinar et al., 2007;
Steinhardt et al., 2008; Zhao et al., 2012), the causes and conse-
quences of YAP1 activation have not been defined, nor have
causal roles for Hippo signaling in the genesis of prostate cancer
been established.
RESULTS
Age-Dependent Prostate Tumors Develop in Transgenic
Mice Expressing High Levels of ERG
To determine the consequences of ERG overexpression in
prostate epithelium in vivo, we performed extensive longitudinal
analyses of a GEM model, Tg(Pbsn-ERG)1Vv, designed to ex-
press high levels of ERG in prostate epithelium (Klezovitch
et al., 2008). This mouse line integrated the transgene in an in-
tergenic region on chromosome 1, expresses ERG at levels
comparable to primary human prostate cancers with ERG rear-
rangements, and displays transcriptional changes that signifi-798 Cancer Cell 27, 797–808, June 8, 2015 ª2015 Elsevier Inc.cantly correlate with those identified in ERG+ human prostate
tumors (Figure 1A; Figure S1; Tables S1A–S1C). We found
that aged Tg(Pbsn-ERG)1Vv mice develop prostate tumors
and have a shorter lifespan than wild-type littermates (Fig-
ure 1B). Overall, approximately 50% of Tg(Pbsn-ERG)1Vv
transgenic mice aged 2 years and older developed prostate
tumors, while none were found in wild-type littermates (Table
1). This is consistent with a lack of spontaneous prostate can-
cer in aged wild-type mice (Sharma and Schreiber-Agus, 1999).
The level of ERG transgene expression was important, as we
found no prostate tumors in aged mice from a different line
Tg(Pbsn-ERG)8Vv (n = 9), which expressed substantially lower
levels of ERG (Figure S1A).
We observed several prostate tumor phenotypes in aged
Tg(Pbsn-ERG)1Vv mice, including adenocarcinomas, sarcoma-
toid carcinomas (epithelial-mesenchymal transition [EMT]-like
epithelial tumor, confirmed by showing pan-keratin expression),
as well as stromal-type tumors (Figures 1 and 2; Figures
S1D–S1F; Table 1). Similar to most human prostate cancers,
adenocarcinomas in the Tg(Pbsn-ERG)1Vv mice are composed
primarily of luminal (Keratin8+, Androgen Receptor high,
Nkx3.1+) cells; however, small numbers of basal cells (Keratin5+)
were present close to the margins of these tumors (Figures 1E–
1M; Figures S1G–S1M). The sarcomatoid carcinomas in the
Tg(Pbsn-ERG)1Vv mice were usually quite large and contained
many actively dividing (BrdU+) cells (Figure 2). We conclude
that the expression of ERG in prostate epithelial cells in vivo,
at levels that are clinically relevant, is sufficient to cause the
slow and partially penetrant emergence of age-related prostate
tumors, a disease course that parallels prostate cancer develop-
ment in men.
Activation of Hippo Pathway Target Genes in ERG
Transgenic Mice
To determine the primary mechanisms responsible for the
tumorigenic function of ERG, we analyzed gene expression
changes in the prostates of Tg(Pbsn-ERG)1Vv mice prior to tu-
mor development. Analyses of well-established gene targets of
the canonical Wnt, Hedgehog, TGFb, Notch, and Hippo
signaling pathways revealed epithelium-specific activation of
Ctgf, a gene directly regulated by the Hippo pathway transcrip-
tional activator YAP1 (Figures 3A–3E). In the canonical Hippo
signaling pathway, YAP1 activity is negatively regulated by
phosphorylation at S127 by the LATS1/2 kinases, which results
in cytoplasmic retention and inactivation of YAP1 (Zhao et al.,
2011). We hypothesized that as yet undefined targets of ERG
reduced YAP1 S127 phosphorylation, resulting in elevated
YAP1 activity and consequent upregulation of Ctgf. However,
we observed no reduction in YAP1 S127 phosphorylation or
LATS1/2 inactivation in Tg(Pbsn-ERG)1Vv prostates compared
with controls (Figure 3F). Moreover, we found that YAP1 was
prominently expressed and localized to the nucleus in luminal
epithelial cells in both wild-type and ERG transgenic mice (Fig-
ures 3G and 3H). These experiments indicate that the
enhanced Ctgf expression in Tg(Pbsn-ERG)1Vv prostates is
not due to decreased activity of LATS1/2 of the Hippo signaling
pathway, though the findings did not preclude alternative
mechanisms leading to the augmentation of YAP1 signaling
and consequent Ctgf upregulation.
Figure 1. Prostate Tumors in Aged
Tg(Pbsn-ERG)1Vv Mice
(A) Western blot (WB) analysis of ERG protein
expression in primary human prostate tumors,
ventral prostates from 8.5-month-old wild-type
(WT) and Tg(Pbsn-ERG)1Vv (Pbsn-ERG) mice, and
the VCaP cell line.
(B) Kaplan-Meier survival curves of Tg(Pbsn-ERG)
1Vv (Pbsn-ERG) and control wild-type littermate
mice. n = 15 for wild-type. n = 24 for Pbsn-ERG.
Log rank test was used to determine statistical
significance.
(C) Gross appearance of urogenital tract organs in
20-month-old Pbsn-ERG male. The arrow points
to the primary prostate tumor.
(D–M) H&E (D and F), immunohistochemical (E and
G–K), and immunofluorescence (L and M) staining
of prostatic adenocarcinoma in 20-month-old
Tg(Pbsn-ERG)1Vv (Pbsn-ERG) male. Areas out-
lined in (D, left) and (E, left) are shown at higher
magnification in (D, right) and (E, right). Staining
was performed with indicated antibodies. The
scale bar in (D) represents 2 mm in (D, left),
0.14mm in (D, right), 0.2mm in (E, left), 45 mm in (E,
right), 36 mm in (F)–(K), and 12 mm in (L) and (M).
See also Figure S1 and Table S1.Overexpression of ERG in Non-tumorigenic Prostate
Epithelial Cells Activates YAP1 Target Genes and
Increases YAP1-Mediated Transcriptional Output
To investigate the role of ERG in regulation of Hippo signaling in
prostate epithelial cells in culture using gain-of-function experi-
ments, we engineered RWPE-1 cells to stably express ERG,
constitutively active YAP1 (Yap1S127A [Dong et al., 2007]), or
both ERG and YapS127A (Figures 4A–4D; Figure S2A). The
RWPE-1 cell line is a model of immortalized non-tumorigenic hu-
man basal epithelial cells, which do not express endogenous
ERG (Bello et al., 1997; Litvinov et al., 2006). RNA sequencing
(RNA-seq) analysis identified a significant overlap between
genes upregulated through ERG expression and those regulated
through Yap1S127A (p < 0.001; Figures 4A and 4B; Tables S2
and S3). Similarly, gene set enrichment analysis (GSEA)
confirmed prominent similarities between ERG and Yap1S127A
transcriptional programs (Figure 4D). qRT-PCR analysis not only
confirmed ERG-mediated upregulation of the ‘‘Hippo pathway
down’’ signature genes CTGF and ENC1 (Mohseni et al., 2014)
but also demonstrated that ERG was able to increase their
expression levels even in cells expressing constitutively active
Yap1S127A, which cannot be inactivated by phosphorylationCancer Cell 27, 797–at S127 by LATS1/2 (Figure 4C). More-
over, analyses of YAP1 S127 phosphory-
lation and the Hippo pathway kinases,
MST1 and LATS1, demonstrated that
ERG does not significantly impact their
levels or activity (Figures S2A and S2B).
The actin cytoskeleton can in some
cases regulate YAP1 activity indepen-
dently from the Hippo/LATS phosphory-
lation cascade (Dupont et al., 2011). As
expected, disruption of the actin cyto-skeleton prominently downregulated expression of CTGF in
RWPE-1 cells; however, this did not erase or decrease the differ-
ences in CTGF expression levels between the control and ERG
expressing cells, indicating that ERG does not influence YAP1
activity via the actin cytoskeleton (Figures S2C–S2E).
YAP1/TAZ Are Necessary for ERG-Mediated
Transformation and Invasion of Non-tumorigenic
Prostate Epithelial Cells
We next analyzed the functional importance of YAP1/TAZ in
mediating ERG-associated malignant phenotypes in RWPE-1
cells. The recently developed 3D organoid prostate culture sys-
tem faithfully recapitulates the in vivo phenotypes and enables
mechanistic studies of prostate development, homeostasis,
and cancer (Karthaus et al., 2014). We found that overexpression
of ERG significantly promotes growth of RWPE-1 cells (RWPE-
ERG) in the 3D organoid prostate culture system (Figures 4E
and 4F). Importantly, YAP1/TAZ were necessary for this ERG-
mediated transforming phenotype, because the knockdown of
YAP1 and TAZ using two independent sets of small interfering
RNA (siRNA) oligos erased the growth differences between
RWPE-Crtl and RWPE-ERG cells (Figures 4G and 4H). Similarly,808, June 8, 2015 ª2015 Elsevier Inc. 799
Table 1. Prostate Tumor Incidence and Tumor Types in Tg(Pbsn-
ERG)1Vv and Control Littermate Mice
Genotype
Prostate
Gland Tumor Adenocarcinoma
Sarcomatoid
Carcinoma
Stromal
Tumor
Tg/+ Tg(Pbsn-
ERG)1Vv
16/25*** 5/25 3/25 8/25
+/+ Wild-type
littermates
0/15 0/15 0/15 0/15
Numbers denote mice with indicated tumors relative to the number of
mice analyzed. The prostate glands were analyzed in mice euthanized
at morbidity. The ages varied between 16 and 30 months in Tg(Pbsn-
ERG)1Vv and between 16 and 38 months in wild-type littermate mice.
Significance of the association between prostate tumor development
and genotype was tested using two-tailed Fisher’s exact test.the stable knockdown of YAP1 using two independent lentiviral
small hairpin RNA (shRNA) constructs also erased the growth
differences between RWPE-Ctrl and RWPE-ERG cells in this cul-
ture system (Figures S2F and S2G). We also found that gain of
function of YAP1 (YAP1S127A) was sufficient for stimulation of
growth of RWPE-1 (RWPE-YAP1) cells in the 3D organoid pros-
tate culture system (Figure 4I). Moreover, ERG and YAP1 prom-
inently cooperated with each other in stimulation of growth of
RWPE-1 (RWPE-ERG+YAP1) cells in this culture system (Fig-
ure 4I). These data indicate that YAP1/TAZ were both necessary
and sufficient for ERG-mediated transformation of RWPE-1
cells. In addition to promoting the growth of RWPE-1 cells in
the 3D organoid prostate culture system, overexpression of
ERG prominently stimulated formation of RWPE-1 cell colonies
in soft agar assays in media containing 1% fetal bovine serum
(Figure S2H). The stable knockdown of YAP1 using two indepen-
dent shRNA constructs erased the differences between RWPE-
Crtl and RWPE-ERG cells, confirming that YAP1 was necessary
for ERG-mediated transformation of RWPE-1 cells (Figure S2H).
ERG has been shown to promote the invasive behavior of
human prostate epithelial cells (Brenner et al., 2011; Klezovitch
et al., 2008; Tomlins et al., 2008). Interestingly, constitutively
active YAP1 also promotes EMT and cell invasion across a spec-
trum of tumor types (Lamar et al., 2012; Overholtzer et al., 2006).
Therefore, we asked whether ERG utilizes YAP1/TAZ in the
development of this phenotype. As expected, overexpression
of ERG promoted matrigel invasion of RWPE-1 (RWPE-ERG)
cells (Figure S2I). Importantly, knockdown of YAP1 and TAZ
erased the differences in invasion between RWPE-Ctrl and
RWPE-ERG cells, indicating that YAP1/TAZ are necessary for
ERG-mediated stimulation of cell invasion (Figure S2I).
ERG Interacts with TEAD-Occupied Chromatin Regions,
Increases Histone Acetylation, and Promotes YAP1-
Dependent Transcription
Since ERG and YAP1 both localize to the nucleus (Figures 1L,
3G, and 3H), we hypothesized that ERG directly binds and acti-
vates YAP1 target genes. YAP1 associates with several distinct
transcription factors, though members of the TEAD family are
most directly responsible for the proto-oncogenic function of
YAP1 (Liu-Chittenden et al., 2012; Zhao et al., 2008). Chromatin
immunoprecipitation sequencing (ChIP-seq) experiments with
RWPE-Ctrl and RWPE-ERG cells identified a highly significant800 Cancer Cell 27, 797–808, June 8, 2015 ª2015 Elsevier Inc.overlap between TEAD4 and ERG peaks in RWPE-ERG cells
with closely positioned ERG-TEAD4 recognition motifs (Figures
4J–4L). Of overlapping ERG-TEAD4 peaks in RWPE-ERG cells,
75% were already occupied by TEAD4 in control RWPE-Ctrl
cells, indicating that ERG does not function as a pioneering fac-
tor for TEAD4 chromatin binding. Analyses of potential changes
in histone modifications in shared ERG-TEAD4 peaks at the pro-
moters of Hippo gene targets, CTGF and ENC1, revealed an
ERG-dependent increase in H3K9/14 acetylation, a chromatin
mark highly localized to the 50 regions of transcriptionally active
human genes (Liang et al., 2004) (Figure 4M).
To determine whether ERG acts directly on the promoters of
Hippo target genes, we performed luciferase assays with a
CTGF promoter. ERG significantly increased YAP1/TEAD4-
mediated CTGF transcription, and both ERG-binding motifs in
the CTGF promoter and ERG’s ability to bind to DNA were
required for this transcriptional activation (Figures S2J–S2L).
Overall, we conclude that in prostate epithelial cells ERG binds
to many TEAD-interacting regions of chromatin, increases the
histone H3K9/14 acetylation, and promotes the transcriptional
activity of YAP1 target genes.
ERG Maintains YAP1 Expression in Neoplastic Luminal
Prostate Epithelial Cells by Controlling H3K9/14
Acetylation of the YAP1 Promoter
To complement the gain-of-function studies, we evaluated the
effects of suppressing ERG and YAP1/TAZ activity in a human
luminal epithelial line, VCaP, that endogenously expresses high
ERG levels by virtue of a TMPRSS2-ERG rearrangement (Tom-
lins et al., 2005). RNA-seq analysis of VCaP with siRNAs target-
ing ERG or YAP1 identified a highly significant overlap between
genes altered by loss of ERG and those altered by loss of YAP1/
TAZ activity (p < 0.001; Figures 5A–5D; Tables S4 and S5). ChIP-
seq analysis of ERG and TEAD4 chromatin-binding sites
confirmed a highly significant overlap between ERG and
TEAD4 peaks in VCaP cells, with closely positioned ERG-
TEAD4 recognition motifs (Figures 5E and 5F).
Of interest, we found that suppressing endogenous ERG in
VCaP cells by siRNAs significantly decreased the expression
of endogenous YAP1, as determined by RNA-seq, qRT-PCR,
and western blot (Figure 5D; Figure S3A; Table S4). We found
that both ERG and TEAD4 peaks were present at the transcrip-
tional start site of YAP1, and ChIP-re-ChIP experiments revealed
the co-occupancy of ERGand TEAD4 at theYAP1 promoter (Fig-
ure 5G; Figure S3B). Quantitative ChIP analyses demonstrated
substantial downregulation of H3K9/14 acetylation at YAP1
and ENC1 promoters in siERG VCaP cells (Figure 5H; Figures
S3C and S3D). These findings support a direct role for ERG in
the maintenance of YAP1 expression in human luminal VCaP
cells by controlling H3K9/14 acetylation of the YAP1 promoter.
ERG and YAP1 Are Co-expressed in a Subset of Primary
Human Prostate Cancers and YAP1 Associates with
Adverse Outcomes
To assess the relationships between ERG and YAP1 in human
prostate cancer, we performed immunostaining of tissue micro-
arrays (TMAs) with anti-ERG and anti-YAP1 antibodies. Surpris-
ingly, in contrast to the mouse prostate, YAP1 was expressed in
the basal, but not in luminal, epithelial cells in normal human
Figure 2. Large Sarcomatoid Carcinoma
Tumor in Prostate Gland of Tg(Pbsn-ERG)
1Vv Mice
(A) Histology of prostate gland from 26-month-old
Tg(Pbsn-ERG)1Vv mouse.
(B) Histology of prostate gland from 38-month-old
wild-type mouse.
(C–H) Serial sections of the tumor and the adja-
cent, uninvolved epithelium from Tg(Pbsn-ERG)
1Vv mouse stained with H&E (C), anti-E-cadherin
(epithelial cell marker; D), anti-Androgen Receptor
(AR, luminal cell marker; E), anti-pan-cytokeratin
(epithelial cell marker; F), anti-keratin 5 (basal
epithelial cell marker; G) and anti-BrdU (prolifer-
ating cell marker; H).
The scale bar in (A) represents 4 mm in (A) and (B)
and 80 mm in (C)–(H).prostate glands (Figure 5I; Figures S3E and S3F). Significantly, in
human luminal-type prostate carcinomas, YAP1 protein was ex-
pressed in 55% (64 of 116) of the tumors evaluated (Figure 5I). In
the analyzed cohort, 44% (52 of 116) of the cancers also ex-
hibited high ERG expression and there was a highly significant
overlap between those primary tumors expressing ERG and
those expressing YAP1 (p = 0.0002) (Figure 5I). Further, the
expression of nuclear YAP1 in primary tumors was significantly
associated with tumor recurrence after primary treatment (p =
0.0002) (Figure S3F). We conclude that increased YAP1 expres-
sion in transformed luminal epithelium may be an important
consequence of ERG activity in human prostate cancers.
YAP1 Is Necessary for ERG-Mediated Transformation
and Invasion of ERG-Positive Human Prostate Cancer
Cells
We next analyzed the functional importance of YAP1/TAZ in
mediating ERG-associated malignant phenotypes in VCaP
cells. Knockdown of ERG or YAP1/TAZ decreased the invasion
of VCaP cells (Figure S4A). In addition, suppression of YAP1/
TAZ in VCaP cells also decreased their anchorage-dependent
and -independent growth (Figures S4B–S4D). Since ERG is
necessary for the maintenance of YAP1 expression in VCaP
cells, we analyzed whether restoration of YAP1 rescues pheno-
types resulting from ERG suppression. Indeed, re-expression of
YAP1 completely rescued the invasion and cell growth pheno-
types in VCaP cells transduced with shRNAs targeting ERG
(Figures S4E–S4G). shERG-mediated decrease in the soft-agar
colony formation and orthotopic xenograft growth of VCaP cells
were significantly, but partially, rescued by re-expression ofCancer Cell 27, 797–exogenous YAP1, suggesting that the
direct control of YAP1 gene expression
can account for many, but not all, cancer
relevant phenotypes of ERG in VCaP cells
(Figures S4H–S4J).
The YAP1 Inhibitor Verteporfin
Suppresses ERG-Positive Prostate
Carcinoma Growth In Vivo
The in vitro studies indicated that YAP1 is
responsible for a significant part of onco-genic programs activated by ERG in prostate cancer. To eval-
uate the in vivo effects of suppressing YAP1 in the context of
ERG-driven cancer, we evaluated a small molecule FDA-
approved drug Verteporfin, which was recently identified as a
specific inhibitor of YAP1 (Liu-Chittenden et al., 2012). We found
that the systemic administration of Verteporfin substantially in-
hibited the growth of pre-established orthotopic ERG-positive
VCaP xenografts in vivo (Figures 6A–6D). In contrast, Verteporfin
treatment did not have a statistically significant impact on the
growth of pre-established orthotopic ERG-negative PC3 xeno-
grafts (Figures 6E–6H). As the direct activity of ERG and other
transcription factors are challenging to inhibit in vivo, the sup-
pression of YAP1 by Verteporfin may have clinical utility in treat-
ing prostate cancers with ERG rearrangements.
Genetic Activation of YAP1 in Mouse Prostate
Epithelium Results in Age-Dependent Development of
Prostate Tumors
While ERG expression in prostate epithelial cells promotes a
YAP1-mediated transcriptional program, the causal effects of
activating this program in the context of prostate neoplasia
in vivo are not known. To address this question, we utilized trans-
genic mice carrying a doxycycline (Dox)-inducible allele of
constitutively active YAP1 (Yap1S127A) (Camargo et al., 2007).
Prostate epithelium-specific Cre mice (Pbsn-Cre4 [Wu et al.,
2001]) were utilized for Cre-mediated activation of Dox-depen-
dent transactivator (rtTA) (Figures 7A and 7B). At 3 months of
age, we exposed these Pbsn-Cre4/Rosa26-LSL-rtTA/TetOP-
YAP1S127A (YAP1-GOF) mice to Dox-containing feed and
examined their prostate glands at different time intervals808, June 8, 2015 ª2015 Elsevier Inc. 801
Figure 3. Upregulation of Hippo Pathway
Target Gene Ctgf in Prostates of Tg(Pbsn-
ERG)1Vv Mice
(A) RT-PCR analysis of major gene targets of the
canonical Wnt, Hedgehog, TGFb, Notch, and
Hippo signaling pathways in prostate glands
from 3- and 10-month-old Tg(Pbsn-ERG)1Vv
(Pbsn-ERG) and wild-type littermate (WT) mice.
(B) qRT-PCR analysis of direct Hippo pathway
gene target Ctgf in prostate glands from
10-month-old Pbsn-ERG and wild-type littermate
mice. Individual mice (left) and wild-type and
Pbsn-ERG group (right) comparisons are shown.
Data represent mean ± SD. Student’s t test was
used to determine statistical significance.
(C) Immunohistochemical analysis of CTGF
expression in prostate glands from 5-month-old
wild-type (left) and Pbsn-ERG (right) littermate
mice.
(D and E) In situ hybridization analysis of Ctgf
expression in prostate glands from 5-month-old
wild-type (left) and Pbsn-ERG (right) littermate
mice using anti-sense (D) and control sense (E)
probes.
For (C)–(E), tissue sections from two WT and two
Pbsn-ERG animals were placed on the same slide
and all the incubation times and treatments were
identical for both genotypes.
(F) Western blot analysis of total protein extracts
from the prostates of 11-month-old wild-type (WT)
and Pbsn-ERG mice with anti-phospho(S127)-
YAP1 (P-YAP1), anti-Yap1, anti-TAZ, anti-CTGF,
anti-phospho(Thr183)-MST1 (P-MST1), anti-
MST1, anti-phospho(S909)-LATS1 (P-LATS1),
anti-LATS1, anti-ERG, and anti-b-actin anti-
bodies.
(G) Immunohistochemical staining of ventral
prostates and a prostate tumor from 2.5-year-old
wild-type and Pbsn-ERG mice with anti-YAP1
antibodies.
(H) Confocal sections of ventral prostate from
5month-old wild-type mouse immunostained with
rabbit anti-YAP1, guinea pig anti-keratin 5, and rat
anti-keratin 8.
The scale bar in (G) represents 40 mm in (C)–(E) and
(G) and 8.5 mm in (H).thereafter. We found that similar to the prostate-specific ERG
transgenic mice, young YAP1-GOF animals presented with min-
imal phenotypes, while aged YAP1-GOF animals developed
prostate tumors with incidence rates and histological pheno-
types similar to the prostate gland tumors in Tg(Pbsn-ERG)1Vv
mice (Figures 7C–7J). These data demonstrate that activation
of a YAP1 transcriptional program in mouse prostate epithelium
in vivo results in the development of partially penetrant age-
related prostate tumors. Further, RNA-seq analysis of prostate
glands from YAP1-GOF mice revealed that transcriptional
changes induced by YAP1 activation in prostate epithelium
in vivo significantly overlapped with the transcriptional program
activated by prostate epithelium-specific expression of ERG
(Figures S5A–S5C; Tables S6, S7, and S8). Importantly, analyses
of human prostate cancer datasets revealed a highly significant
overlap between the murine prostate-gland specific YAP1-GOF802 Cancer Cell 27, 797–808, June 8, 2015 ª2015 Elsevier Inc.gene signature and human ERG-positive prostate carcinomas
(Figures S5D–S5F).
DISCUSSION
Chromosome rearrangements driving high levels of ERG expres-
sion occur frequently in prostate cancers, an observation that
strongly implicates ETS family oncogenes as major contributors
to the genesis and potentially the progression of this disease.
However, GEM strategies that have been quite useful in confirm-
ing cause and effect relationships for numerous other onco-
genes and tumor suppressor pathways have not identified clear
mechanisms bywhich ERG contributes to prostate neoplasia. To
date, the reported phenotypes resulting from engineered ERG
expression in the mouse prostate have been quite modest
(Baena et al., 2013; Carver et al., 2009a, 2009b; Chen et al.,
Figure 4. ERG Binds to TEAD4-Interacting Regions of Chromatin and Transactivates Hippo Pathway Target Genes in Immortalized Prostate
Epithelial Cells
(A and B) Significant overlap of gene expression changes induced by overexpression of ERG and constitutively active YAP1. Gene expression in RWPE-1 cells
transduced with empty vectors (RWPE-Ctrl), ERG (RWPE-ERG), or YAP1S127A (RWPE-YAP1S127A) was analyzed by RNA-seq. n = 2 per each genotype. (A)
Heatmap. (B) Overlap between significantly (Q < 0.05) upregulated genes. Two-tailed Chi-square with Yates correction was used to determine statistical
significance.
(C) qRT-PCR analyses of two Hippo pathway target genes CTGF and ENC1 in RWPE-Ctrl (Ctrl), RWPE-ERG (ERG), RWPE-YAP1S127A (YAP1), and RWPE-ERG
and YAP127A (ERG YAP) expressing RWPE-1 cells. Data represent mean ± SD (n = 3) from one of three independent experiments. Student’s t test was used to
determine statistical significance.
(D) GSEA analysis of similarities between ERG-mediated gene expression changes and YAP1S127A upregulated genes.
(E and F) Brightfield images (E) and size quantitation (F) of RWPE-Ctrl (Ctrl) and RWPE-ERG (ERG) cell colonies formed after 6 days in 3D organoid culture system.
The graph shows mean ± SD. nR 40. Student’s t test was used to determine statistical significance. The scale bar represents 100 mm.
(G) Western blot (WB) analyses of RWPE-1 cells transfected with indicated siRNA oligos and analyzed with indicated antibodies.
(H) Colony size quantitation of RWPE-Ctrl (Ctrl) and RWPE-ERG (ERG) cells in 3D organoid culture system transfected with indicated siRNA oligos. The graph
shows mean ± SD. nR 60. Student’s t test was used to determine statistical significance.
(I) Colony size quantitation of RWPE-Ctrl (Ctrl), RWPE-ERG (ERG), RWPE-YAP1S127A (YAP1), and RWPE-ERG + YAP127A (ERG + YAP1) cells in 3D organoid
culture system. The graph shows mean ± SD. nR 44. Student’s t test was used to determine statistical significance.
(J) UCSC genome browser views of ChIP-seq data from RWPE-Ctrl and RWPE-ERG cells using IgG, anti-ERG, and anti-TEAD4 antibodies.
(K) Highly significant overlap between positions of TEAD4 and ERG peaks in RWPE-ERG cells (hypergeometric p value = 3.761525e-263 calculated by
Bioconductor package ‘‘ChIPPeakAnno’’).
(L) Tendency toward close juxtaposition of ERG (A/C)GGAA(G/A) and TEAD4 GGAAT(G/T)(T/C) recognition motifs in ERG-TEAD4 overlapping peaks in RWPE-
ERG cells.
(M) qPCR analysis of ChIP experiments from RWPE-Ctrl and RWPE-ERG cells using indicated antibodies. Data represent mean ± SD (n = 4) from one of three
independent experiments. Student’s t test was used to determine statistical significance.
See also Figure S2 and Tables S2 and S3.2013; King et al., 2009; Klezovitch et al., 2008; Tomlins et al.,
2008). One possibility for the lack of oncogenic activity hinges
on the level of ERG expression. Dependence of a phenotype
on the level of proto-oncogene expression is frequently seen in
transgenic animals (Smith et al., 2006). The synthetic probasin
promoter that confers prostate epithelial specificity provides
relatively weak levels of prostate-specific ERG expression. For
example, while we generated 14 Tg(Pbsn-ERG) founder lines,
only two lines with highest levels of ERG expression displayphenotypic changes and only the line with the highest level of
ERG expression, which achieves levels seen in human prostate
cancers with ERG rearrangements, develops overt tumors in
the prostate gland.
A second consideration regarding prostate cancer pheno-
types concerns the age-related dependency of prostate neo-
plasms. Human prostate cancer is highly associated with
advanced age and is very infrequently diagnosed in men under
the age of 50. Mice do not develop spontaneous prostateCancer Cell 27, 797–808, June 8, 2015 ª2015 Elsevier Inc. 803
Figure 5. ERG Maintains YAP1 Expression in Human Prostate Cancer Cells
(A–C) Significant concordance between ERG and YAP1/TAZ gene expression programs in VCaP cells. Gene expression determined by RNA-seq of VCaP cells
transiently transfected with non-targeting siRNA (siCtrl, n = 2), siRNAs targeting ERG (siERG, n = 2, using two independent siRNA oligos), and siRNAs targeting
YAP1/TAZ (siYAP1/TAZ, n = 2, using two independent siRNA oligo mixtures). (A) Heatmap. (B) Overlap between significantly (Q < 0.05) upregulated and
downregulated genes. (C) GSEA analysis of overlap between siERG-mediated gene expression changes and siYAP/TAZ downregulated genes. Two-tailed Chi-
square with Yates correction was used to determine statistical significance in (B).
(D) Western blot (WB) analysis of VCaP cells transfected with indicated siRNA oligos. Numbers indicate relative expression values, with the value in siCtrl
adjusted to 1.
(E) Highly significant overlap between positions of TEAD4 and ERG peaks in VCaP cells (hypergeometric p value = 0 calculated by Bioconductor package
‘‘ChIPPeakAnno’’).
(F) Tendency toward close juxtaposition of ERG (A/C)GGAA(G/A) and TEAD4 GGAAT(G/T)(T/C) recognition motifs in ERG-TEAD4 overlapping peaks in
VCaP cells.
(G) UCSC genome browser views of ChIP-seq data from VCaP cells using IgG, anti-ERG, and anti-TEAD4 antibodies.
(H) qPCR analysis of ChIP experiments from siCtrl, siERG-1, or siERG-2 oligo transfected VCaP cells using indicated antibodies. Data represent mean ± SD (n = 4)
from one of three independent experiments. Student’s t test was used to determine statistical significance.
(I) Significant correlation between ERG expression and presence of nuclear YAP1 in primary human prostate tumors. Immunohistochemical (IHC) staining of
prostate cancers (PC1 and PC2) was performed with ERG and YAP1 antibodies. Note that YAP1 is strongly expressed in benign basal but not benign luminal
epithelial cells (arrows), but it is present in neoplastic luminal cells in a subset of human prostate carcinomas. The star indicates a histologically benign prostatic
gland. The scale bar represents 50 mm.
See also Figure S3 and Tables S4 and S5.cancer during their normal lifespan (Sharma and Schreiber-
Agus, 1999). Thus, models that accurately reflect disease
pathogenesis may exhibit long periods of latency. Consistent
with these observations, the prostate tumors that developed
in Tg(Pbsn-ERG)1Vv mice generally occurred between 2 and
3 years of age and were focal, involving subsets of epithelial
cells with transgene expression. Therefore, even high levels
of ERG in mouse luminal prostate epithelial cells are not suffi-
cient to drive the rapid and consistent development of carci-
nomas, indicating that in addition to ERG expression other
genetic or epigenetic changes must occur for frank tumor
initiation.
A substantial proportion of the prostate tumors that developed
in aged Tg(Pbsn-ERG)1Vvmice are either stromal tumors, which
do not express epithelial cell markers, or sarcomatoid carci-
nomas expressing both epithelial and stromal cell markers.
Since we did not detect ERG transgene expression in the pros-804 Cancer Cell 27, 797–808, June 8, 2015 ª2015 Elsevier Inc.tate stromal cell compartment of Tg(Pbsn-ERG)1Vvmice (Klezo-
vitch et al., 2008), the origin of the stromal tumors in these aged
mice is not clear. Tumors expressing mesenchymal cell markers
may originate either in stromal cells expressing very low levels of
a transgene or in epithelial cells, which then undergo a prominent
EMT and lose markers of epithelial differentiation. The presence
of sarcomatoid carcinomas expressing both epithelial and stro-
mal cell markersmay represent an intermediate EMT phenotype.
While sarcomatoid carcinoma is rarely seen in human prostate
cancer, these tumors have epithelial origin (Rodrigues et al.,
2015). Further, mouse prostate epithelial cells readily undergo
EMT and present with sarcomatoid carcinomas, which is seen
in mice with deletions of Tp53, or the activation of K-Ras or
COUP-TFII in prostate epithelium (Martin et al., 2011; Mulholland
et al., 2012; Qin et al., 2013; Vinall et al., 2012).
The generation of a GEMmodel that recapitulates the levels of
ERG found in human prostate epithelium made it possible to
Figure 6. YAP1 Inhibitor Verteporfin Dis-
plays Prominent Negative Impact on the
Growth of Pre-established ERG-Positive
Orthotopic Human Prostate Tumors
VCaP (ERG-positive) or PC3 (ERG-negative) hu-
man prostate cancer cells were injected into the
anterior lobe of the prostate gland of non-obese
diabetic severe combined immunodeficiency
mice, and tumors were allowed to establish for
7 weeks without any treatment. Animals were
separated into two random groups, which were
treated with intraperitoneal injection of Verteporfin
(or vehicle) every 2 days at 100 mg/kg for 3 weeks.
Resulting tumors were excised and analyzed.
(A) VCaP gross tumor appearance.
(B) Quantitation of VCaP tumor volume. Data
represent mean ± SD. Student’s t test was used to
determine statistical significance.
(C and D) TissueFAX scanned and stitched images
of H&E staining of VCaP tumor sections at low (C)
and high magnifications (D).
(E) PC3 gross tumor appearance.
(F) Quantitation of PC3 tumor volume. Data
represent mean ± SD. Student’s t test was used to
determine statistical significance.
(G and H) TissueFAX scanned and stitched images of H&E staining of PC3 tumor sections at low (G) and high magnifications (H).
The scale bar in (C) represents 2.5 mm in (C) and (G) and 50 mm in (D) and (H).
See also Figure S4.establish a connection between ERG and the transcriptional
output of the Hippo signaling pathway, which is controlled by
YAP1/TAZ transcriptional co-activators. We identified two
mechanisms by which ERG regulates Hippo pathway signaling
(Figure 7K). First, we found that in prostate epithelial cells ERG
binds to TEAD-occupied regions of chromatin, increases histone
acetylation at these sites, and amplifies the transcriptional
output controlled by YAP1/TEAD. We also determined that
ERG binds to the YAP1 promoter and is required for YAP1
expression in VCaP human luminal prostate cancer cells, identi-
fying a second mechanism directly connecting ERG and YAP1-
dependent regulation of transcription. This second mechanism
is not apparent in mouse prostate epithelium and in basal-type
human prostate epithelial cells, which both already express
ample levels of endogenous YAP1. However, it is readily detect-
able in human luminal-type prostate epithelial cells, which do not
express YAP1 under normal conditions and require high levels of
ERG to drive YAP1 expression.
Mice with prostate epithelium-specific activation of YAP1
develop phenotypes that are remarkably similar to those
observed in Tg(Pbsn-ERG)1Vv mice, suggesting that the activa-
tion of YAP1-mediated transcriptional output is an important part
of ERG function in the prostate gland. While activation of YAP1 in
a variety of mouse organ systems causes dramatic stimulation of
cell proliferation and growth, mouse prostate is resistant to
YAP1-mediated transformation, with focal tumors appearing
only in aged individuals. We found that unlike in human prostate
epithelium, endogenous nuclear YAP1 is abundantly present in
mouse luminal prostate epithelial cells, thus potentially making
the mouse prostate resistant to both ERG and YAP1-mediated
transformations, since an additional increase in YAP1-mediated
transcriptional output is unlikely to have a profound physiological
impact in this environment.The finding that ERG and YAP1 are concordantly expressed in
a subset of human prostate cancers provides support for the
clinical relevance of the molecular interactions between these
pathways. The tumors expressing YAP1 generally exhibit an un-
favorable disease course, and consequently, YAP1may serve as
a marker of aggressive disease. It is not clear why certain tumors
with high ERG levels did not express YAP1, though it is notable
that none of such tumors analyzed in our study recurred after
treatment. Though ERG is an attractive candidate for therapeu-
tics due to the very high prevalence of ERG rearrangements in
prostate cancers, in the past it has been challenging to develop
agents capable of disrupting the activity of transcription factors.
As YAP1 appears to regulate critical components of ERG-medi-
ated neoplasia, inhibiting YAP1 is an attractive alternative. Our
preclinical studies demonstrating substantial reductions in
the growth of ERG-expressing prostate cancer by the FDA-
approved YAP1 antagonist Verteporfin indicate that malignant
phenotypes stemming from ERG activity can be suppressed
by targeting YAP1, a finding that opens a more straightforward
path for drug development and clinical applications.
EXPERIMENTAL PROCEDURES
Mice
All animal experiments were done in accordance with protocols approved by
the Institutional Animal Care and Use Committees of Fred Hutchinson Can-
cer Research Center and followed NIH guidelines for animal welfare.
Tg(Pbsn-ERG)1Vv mice (Klezovitch et al., 2008) on 129S1/SvlmJ genetic
background were aged and analyzed at morbidity with wild-type littermates
used as controls. For the generation of prostate-specific YAP1-GOF
mice, double heterozygous Col1a1tm1(tetO-YAP1*)Fcam (Camargo et al., 2007)
and Gt(ROSA)26Sortm1(rtTA,EGFP)Nagy (Belteki et al., 2005) mice were crossed
with hemizygous mice expressing the prostate epithelium-specific
Cre (Tg(Pbsn-cre)4Prb/0) (Wu et al., 2001). Double mutant Gt(ROSA)
26Sortm1(rtTA,EGFP)Nagy/Gt(ROSA)26Sor, Tg(Pbsn-cre)4Prb/0 mice were usedCancer Cell 27, 797–808, June 8, 2015 ª2015 Elsevier Inc. 805
Figure 7. Activation of YAP1 in Prostate Epithelium In Vivo Is Sufficient for the Development of Age-Related Prostate Tumors
(A) Model showing the development of prostate epithelium-specific YAP1-GOF mice.
(B) Western blot (WB) analysis of YAP1, TAZ and b-actin expression in total proteins extracted from ventral prostates of 20-month-old control (WT) and YAP1-
GOF mice.
(C–I) H&E (I) and immunohistochemical (C–H) staining of large prostatic sarcomatoid carcinoma in 14-month-old YAP1-GOFmale. Staining was performed with
anti-androgen receptor (AR), anti-E-cadherin (E-cad), anti-smooth muscle actin (SMA), anti-YAP1 (YAP), anti-pan-cytokeratin (cytoker), and anti-Vimentin
(viment) antibodies. The scale bar in (I) represents 1.4 mm in (I), 0.4 mm in (C)–(H), and 40 mm in Insets.
(J) Prostate tumor incidence and tumor types in YAP1-GOF and control littermate mice. YAP1-GOF—triple mutant Col1a1tm1(tetO-YAP1*)Fcam/Col1a1+, Gt(ROSA)
26Sortm1(rtTA,EGFP)Nagy/Gt(ROSA)26Sor+, Tg(Pbsn-cre)4Prb/0. Control—double mutant Gt(ROSA)26Sortm1(rtTA,EGFP)Nagy/Gt(ROSA)26Sor+, Tg(Pbsn-cre)4Prb/0.
Numbers denotemicewith indicated tumors relative to the number ofmice analyzed. The prostate glandswere analyzed inmice euthanized atmorbidity. The Dox
exposure was started at 3 months of age and varied between 12 and 16 months. Two-tailed Fisher’s exact test was used to determine statistical significance.
(K) Model showing the role of ERG and YAP1 in prostate cancer development. ERE, ERG response element; TRE, TEAD response element.
See also Figure S5 and Tables S6, S7, and S8.as controls. YAP1 GOF and control animals were switched to Doxycycline-
containing food (www.bio-serv.com, #S3888) at 3 months of age and
maintained on this diet until euthanasia. All animals were analyzed as het-
erozygous (knock-in) or hemizygous (transgene) mutants.
Mouse Prostate Gland Histo-pathology
The histological assessment of prostate tumors in Tg(Pbsn-ERG)1Vvmice was
the result of onlinediscussionswith thePathologyPanel ofNCIMouseModelsof
Human Cancer Consortium (MMHCC) Prostate Cancer on July 2, 2012, chaired
by Prof. Robert D. Cardiff (UC Davis). Prostate gland pathology of YAP1-GOF
mice was analyzed by Dr. Maria S. Tretiakova (a board-certified pathologist
with significant experience with the pathology of the prostate gland).
Gene Expression Analyses
Total RNA was extracted with TRIzol (Invitrogen) followed by RNase-free
DNAase treatment (QIAGEN) and an RNeasy RNA purification kit (QIAGEN).
Complementary DNA was prepared with a SuperScript III First-Strand
Synthesis kit (Invitrogen). qPCR was performed with Prism 7900HT (Applied
Biosystems), platinum qPCR mix (Invitrogen), and a Universal ProbeLibrary
kit using the primers, probes, and PCR conditions recommended by the806 Cancer Cell 27, 797–808, June 8, 2015 ª2015 Elsevier Inc.Universal ProbeLibrary assay center (http://lifescience.roche.com/shop/
products/universal-probelibrary-system-assay-design). qPCR data were
normalized to ribosomal protein Rps16. RNA-seq experiments on RNA from
RWPE-1 cells were performed by Beijing Genomics Institute (BGI). The total
RNA samples were treated with DNase I, and themRNAwas enriched by using
the oligo(dT) magnetic beads, fragmented and used for cDNA synthesis. The
library products were sequenced via Illumina HiSeq 2000. The primary reads
were mapped using Tophat2 (Kim et al., 2013), and differential gene
expression was analyzed using EdgeR Bioconductor software. RNA-seq
experiments on RNA from VCaP cells and mouse ventral prostate glands
were performed using an Encore Complete RNA-Seq Library Systems kit
and the Illumina HiSeq 2500 system. The primary reads were mapped using
Tophat2 (Kim et al., 2013), and differential gene expression was analyzed using
CuffDiff (Trapnell et al., 2010) in Galaxy (Blankenberg et al., 2010). In situ
hybridization was performed on frozen sections as described previously (Kle-
zovitch et al., 2004)
Human Prostate Tumor TMAs Staining and Analysis
Informed consent was obtained from all human subjects, and work was
performed in accordance with institutional review board (IRB) approval
(University of Washington IRB number 39053 and Fred Hutchinson IRB
number 460). 127 specimens were obtained from radical prostatectomies per-
formed at the University of Washington, including non-recurrent (n = 64) and
recurrent prostate cancer (n = 63). TMAs were made with duplicate cores
(1 mm) from paraffin embedded tissues. 4-micron TMA sections were depar-
affinized, re-hydrated, rinsed, and blocked for endogenous peroxidase on the
automated immunostainer (Bond III, Leica Biosystems) using manufacturer
recommended protocols and solutions. Then slides were incubated for
15 min with rabbit monoclonal ERG-antibody (Epitomics, clone EP111,
1:400) or rabbit polyclonal anti-YAP1 (Santa Cruz, #sc-15407, 1:100). This
step was followed by 8 min with anti-rabbit Poly-HRP-IgG polymer detection
reagent (Leica Biosystems), visualization with 3,3’’-Diaminobenzidine chro-
mogen, and counterstaining with hematoxylin. The TMA cores were scored
by the pathologist (M.T.) blind to cancer outcomes. The tumors displaying
positivity in >10% tumor nuclei were defined as either ERG-positive or
YAP1-positive.
Statistical Analyses
Statistical significance was determined by Student’s, Fisher’s exact, Mann-
Whitney, or Chi-square tests. p value is indicated by asterisks in the figures:
*p < 0.05; **p < 0.01; ***p < 0.001. Differences at p = 0.05 and lower were
considered statistically significant. In RNA-seq and ChIP-seq analyses, the
differences with q < 0.05 were considered statistically significant.
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